The second US Coronavirus death was reported in EvergreenHealth hospital in Kirkland, Washington; extended-release drugs were shown to cost almost $14 billion more than twice-a-day medications over a 5-year study; the Supreme Court plans to hear the third challenge to the Affordable Care Act in October.
Yesterday, health authorities in King County, Washington, announced that 1 of the 6 individuals infected with coronavirus in a nursing facility in the Seattle suburb of Kirkland had died at EvergreenHealth hospital, with 3 more in critical condition, according to The New York Times. This is the second coronavirus death on US soil and the second to occur at EvergreenHealth hospital, as a man in his 50s with underlying health conditions was reported on Saturday as the first fatality by the CDC. The preparedness of hospitals in handling a potential pandemic in the United States has been questioned, with an additional article posted in the The New York Times showing that only about 62,000 full-featured ventilators were in hospitals across the county in 2010, paling in comparison to the suggestion of nearly 740,000 mechanical ventilators that would be required for a severe influenza outbreak.
According to a study published in JAMA Network Open, prescriptions for extended-release drugs cost the healthcare system almost $14 billion more than would have been spent on equivalent twice-a-day medications, based on Medicare and Medicaid spending between 2012 and 2017. Reported in Reuters, co-study author Ambarish Pandey, MD, University of Texas Southwestern Medical Center in Dallas, highlighted that there is not a huge difference in patient convenience when comparing the 2 regimens, “but the cost difference is remarkable.”
After turning down a motion by the House of Representatives and Democratic-led states this term to review the legality of the Affordable Care Act (ACA), the Supreme Court will hear a third challenge to the ACA, potentially in October, with a decision coming before the November election. The Washington Post reports that the request was submitted by Democratic-controlled states that are fighting a lower court decision that challenged the constitutionality of the law.
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Patients With RA in Remission Withdrawing From TNF Inhibition Show Flare Increases
December 8th 2023New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Patients With RA in Remission Withdrawing From TNF Inhibition Show Flare Increases
December 8th 2023New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
2 Clarke Drive
Cranbury, NJ 08512